Drug information provided by: Merative, Micromedex®
Mirvetuximab soravtansine-gynx injection is used to treat folate receptor-alpha (FRa) positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received 1 to 3 previous treatments. Your doctor will perform a test to check for the FRa tumor before you receive this medicine.
This medicine is to be given only by or under the immediate supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.